30
Participants
Start Date
December 1, 2021
Primary Completion Date
May 6, 2022
Study Completion Date
May 6, 2022
NNC0363-0845
Participants will receive 0.5 nmol/kg NNC0363-0845 s.c. (subcutaneous - under the skin) every 4 hours up to 6 times daily (i.e. 3 nmol/kg/day) for 3 days The study will last for about 6 weeks up to a maximum of 14 weeks
Insulin detemir
Participants will receive 0.083 U/kg insulin detemir s.c. (subcutaneous - under the skin) every 4 hours up to 6 times daily (i.e. 0.5 U/kg/day) for 3 days The study will last for about 6 weeks up to a maximum of 14 weeks
Novo Nordisk Investigational Site, Graz
Lead Sponsor
Novo Nordisk A/S
INDUSTRY